5-HT3 antagonist ondansetron increases apoE secretion by modulating the LXR-ABCA1 pathway

Motoko Shinohara, Mitsuru Shinohara, Jing Zhao, Yuan Fu, Chia Chen Liu, Takahisa Kanekiyo, Guojun Bu

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Apolipoprotein E (apoE) is linked to the risk for Alzheimer’s disease (AD) and thus has been suggested to be an important therapeutic target. In our drug screening effort, we identified Ondansetron (OS), an FDA-approved 5-HT3 antagonist, as an apoE-modulating drug. OS at low micromolar concentrations significantly increased apoE secretion from immortalized astrocytes and primary astrocytes derived from apoE3 and apoE4-targeted replacement mice without generating cellular toxicity. Other 5-HT3 antagonists also had similar effects as OS, though their effects were milder and required higher concentrations. Antagonists for other 5-HT receptors did not increase apoE secretion. OS also increased mRNA and protein levels of the ATB-binding cassette protein A1 (ABCA1), which is involved in lipidation and secretion of apoE. Accordingly, OS increased high molecular weight apoE. Moreover, the liver X receptor (LXR) and ABCA1 antagonists blocked the OS-induced increase of apoE secretion, indicating that the LXR-ABCA1 pathway is involved in the OS-mediated facilitation of apoE secretion from astrocytes. The effects of OS on apoE and ABCA1 were also observed in human astrocytes derived from induced pluripotent stem cells (iPSC) carrying the APOE ε3/ε3 and APOE ε4/ε4 genotypes. Oral administration of OS at clinically-relevant doses affected apoE levels in the liver, though the effects in the brain were not observed. Collectively, though further studies are needed to probe its effects in vivo, OS could be a potential therapeutic drug for AD by modulating poE metabolism through the LXR-ABCA1 pathway.

Original languageEnglish (US)
Article number1488
JournalInternational journal of molecular sciences
Issue number6
StatePublished - Mar 2 2019


  • ABCA1
  • Alzheimer’s disease
  • ApoE
  • Astrocytes
  • LXR
  • Ondansetron

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of '5-HT3 antagonist ondansetron increases apoE secretion by modulating the LXR-ABCA1 pathway'. Together they form a unique fingerprint.

Cite this